Impact of Cyclosporine Levels on the Development of Acute Graft versus Host Disease after Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation

被引:18
|
作者
Garcia Cadenas, Irene [1 ]
Valcarcel, David [1 ,2 ]
Martino, Rodrigo [1 ]
Pinana, J. L. [1 ,3 ]
Barba, Pere [1 ,2 ]
Novelli, Silvana [1 ]
Esquirol, Albert [1 ]
Garrido, Ana [1 ]
Saavedra, Silvana [1 ]
Granell, Miquel [1 ]
Moreno, Carol [1 ]
Briones, Javier [1 ]
Brunet, Salut [1 ]
Sierra, Jorge [1 ]
机构
[1] Univ Autonoma Barcelona, Dept Hematol, Hosp Santa Creu & Sant Pau, Inst Josep Carreras,Banc Sang & Teixits, Barcelona 08025, Spain
[2] Univ Autonoma Barcelona, Hosp Vall Hebron, Dept Hematol, Barcelona 08025, Spain
[3] Hosp Clin Valencia, Dept Hematol, Valencia, Spain
关键词
BONE-MARROW TRANSPLANTS; ACUTE MYELOID-LEUKEMIA; ACUTE-RENAL-FAILURE; STATISTICAL-METHODS; PART; CSA;
D O I
10.1155/2014/620682
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
We analyze the impact of cyclosporine (CsA) levels in the development of acute graft-versus-host disease (aGVHD) after reduced intensity conditioning allogeneic hematopoietic transplantation (allo-RIC). We retrospectively evaluated 156 consecutive patients who underwent HLA-identical sibling allo-RIC at our institution. CsA median blood levels in the 1st, 2nd, 3rd and 4th weeks after allo-RIC were 134 (range: 10-444), 219 (54-656), 253 (53-910) and 224 (30-699) ng/mL; 60%, 16%, 11% and 17% of the patients had median CsA blood levels below 150 ng/mL during these weeks. 53 patients developed grade 2-4 aGVHD for a cumulative incidence of 45% (95% CI 34-50%) at a median of 42 days. Low CsA levels on the 3rd week and sex-mismatch were associated with the development of GVHD. Risk factors for 1-year NRM and OS were advanced disease status (HR: 2.2, P = 0.02) and development of grade 2-4 aGVHD (HR: 2.5, P < 0.01), while there was a trend for higher NRM in patients with a low median CsA concentration on the 3rd week (P = 0.06). These results emphasize the relevance of sustaining adequate levels of blood CsA by close monitoring and dose adjustments, particularly when engraftment becomes evident. CsA adequate management will impact on long-term outcomes in the allo-RIC setting.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation
    Bornhäuser, M
    Schuler, U
    Pörksen, G
    Naumann, R
    Geissler, G
    Thiede, C
    Schwerdtfeger, R
    Ehninger, G
    Thiede, HM
    TRANSPLANTATION, 1999, 67 (04) : 499 - 504
  • [42] Risk factors for acute graft-versus-host disease grades II–IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors—a single centre study
    M Remberger
    J Mattsson
    Z Hassan
    N Karlsson
    K LeBlanc
    B Omazic
    M Okas
    D Sairafi
    O Ringdén
    Bone Marrow Transplantation, 2008, 41 : 399 - 405
  • [43] Lung Transplantation for Chronic Graft Versus Host Disease after Allogeneic Stem Cell Transplantation
    Holm, A. M.
    Riise, G. C.
    Hansson, L.
    Bjortuft, O.
    Brinch, L.
    Simonsen, S.
    Floisand, Y.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2012, 31 (04): : S58 - S59
  • [44] The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation
    S Thepot
    J Zhou
    A Perrot
    M Robin
    A Xhaard
    R P de Latour
    L Ades
    P Ribaud
    A D Petropoulou
    R Porcher
    G Socié
    Leukemia, 2010, 24 : 1852 - 1858
  • [45] Chronic graft-versus-host disease after reduced-intensity stem cell transplantation versus conventional hematopoietic stem cell transplantation
    Busca, A
    Rendine, S
    Locatelli, F
    Sizzano, F
    Dall'Omo, AM
    Rossi, G
    Falda, M
    HEMATOLOGY, 2005, 10 (01) : 1 - 10
  • [46] The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation
    Thepot, S.
    Zhou, J.
    Perrot, A.
    Robin, M.
    Xhaard, A.
    de Latour, R. P.
    Ades, L.
    Ribaud, P.
    Petropoulou, A. D.
    Porcher, R.
    Socie, G.
    LEUKEMIA, 2010, 24 (11) : 1852 - 1858
  • [47] Analysis of Histology's Impact in Patients with Acute Graft versus Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
    Gamez Jimenez, Elena Maria
    Gonzalez Sierra, Pedro Antonio
    Lopez Fernandez, Elisa
    Moratalla Lopez, Lucia
    Mesa Morales, Zoraida
    Romero Aguilar, Antonio
    Jurado Chacon, Manuel
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 375 - 375
  • [48] Impact of chronic graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukaemia: A report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation
    Baron, F.
    Labopin, M.
    Niederwieser, D.
    Vigouroux, S.
    Cornelissen, J.
    Malm, C.
    Vindelov, L.
    Blaise, D.
    Janssen, J.
    Petersen, E.
    Socie, G.
    Nagler, A.
    Rocha, V.
    Mohty, M.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S75 - S75
  • [49] The impact of cyclosporine blood levels on the development of acute graft versus host disease.
    Bottini, PV
    Azevedo, AM
    Gebrin, AC
    Garlipp, CR
    CLINICAL CHEMISTRY, 1998, 44 : A99 - A99
  • [50] MARAVIROC CONCENTRATIONS ARE HIGHLY PREDICTIVE OF ACUTE GRAFT-VERSUS-HOST DISEASE IN REDUCED-INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Ganetsky, A.
    Crisalli, L. M.
    Huffman, A. P.
    Acosta, E. P.
    Mangan, J. K.
    Luger, S. M.
    Loren, A. W.
    Hexner, E. O.
    Frey, N. V.
    Stadtmauer, E. A.
    Hoxie, J. A.
    Vonderheide, R. H.
    Porter, D. L.
    Reshef, R.
    HAEMATOLOGICA, 2016, 101 : 109 - 110